The Moving Average Convergence Divergence (MACD) for LCTX turned positive on August 05, 2022. Looking at past instances where LCTX's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on August 04, 2022. You may want to consider a long position or call options on LCTX as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in of 214 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 155 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
LCTX broke above its upper Bollinger Band on August 04, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.353) is normal, around the industry mean (26.225). P/E Ratio (0.000) is within average values for comparable stocks, (100.314). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.703). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (32.362) is also within normal values, averaging (317.105).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
|Technical Analysis||# Of Indicators||Avg. Odds|
a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions
|MFs / NAME||Price $||Chg $||Chg %|
|Principal SmallCap R5|
|Principal Edge MidCap Institutional|
|ClearBridge Aggressive Growth FI|
|Timothy Plan International A|
|AMG River Road International Value Eq I|
A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with FBIO. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then FBIO could also see price increases.
|FBIO - LCTX|
|IBRX - LCTX|
|GTHX - LCTX|
|VIRX - LCTX|
|ALEC - LCTX|